SWI Initiates Coverage on Hemispherx Biopharma, Inc. Download Research Report – Watch CEO Interview

logo

Marina del Rey, CA – August 3, 2016 – SWI today announced that it has initiated coverage on Hemispherx Biopharma, Inc. (NYSE:HEB). HEB is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection®, the experimental therapeutics Ampligen® and Alferon® LDO. 

SWIResearch_transp 150     

                            RESEARCH REPORT

                   Donwload Button
FAST GROWING LARGE MARKET FOR DEBILITATING DISEASES

Debilitating diseases are a complex mosaic of an estimated 6,000 –8,000 conditions. The US demand for drug delivery products are expected to  expand 10.4 percent annually from $168 Billion in 2016 to $319 billion by 2021. HEB’s product development aims to take advantage of this huge market opportunity.
 
                CEO INTERVIEW ON SMALL CAP NATION
 
           SCN Video 2
 
ACCELERATED PRODUCT DEVELOPMENT THROUGH COLLABORATION
Hemispherx is aggressively pursuing co-development and/or licensing partners for Ampligen® with focus on Immune-Oncology, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and vaccines. The company is also seeking co-development and/or licensing partners for Alferon  to expedite product development and revenue generation.

EXCEPTIONAL INVESTMENT OPPORTUNITY
Hemispherx Biopharma, Inc. is a company that has implemented a structure with promising products pron for extraordinary success in place. We consider HEB  an exceptional investment opportunity that you cannot afford to miss.
 
For more information go to:
 
logo